AR089673A1 - Formulacion de premezcla de dexmedetomidina - Google Patents
Formulacion de premezcla de dexmedetomidinaInfo
- Publication number
- AR089673A1 AR089673A1 ARP130100046A ARP130100046A AR089673A1 AR 089673 A1 AR089673 A1 AR 089673A1 AR P130100046 A ARP130100046 A AR P130100046A AR P130100046 A ARP130100046 A AR P130100046A AR 089673 A1 AR089673 A1 AR 089673A1
- Authority
- AR
- Argentina
- Prior art keywords
- dexmedetomidine
- liquid
- composition
- subject
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Composiciones farmacéuticas que comprenden dexmedetomidina o una sal farmacéuticamente aceptable de la misma en donde la composición se formula como un líquido para la administración parenteral a un sujeto, y en donde la composición se dispone dentro de un contenedor sellado como una premezcla. Las composiciones farmacéuticas se pueden utilizar, por ejemplo, en el cuidado perioperativo de un paciente o para la sedación. Reivindicación 1: Una composición farmacéutica líquida lista para el uso para la administración parenteral a un sujeto, caracterizada en que comprende dexmedetomidina o una sal farmacéuticamente aceptable de la misma en una concentración de aproximadamente 0.005 a aproximadamente 50 mg/mL, dispuesta dentro de un contenedor de vidrio sellado. Reivindicación 6: La composición farmacéutica líquida lista para el uso de la reivindicación 1, caracterizada en que adicionalmente comprende cloruro de sodio en una concentración de entre aproximadamente 0.01 y aproximadamente 2.0 por ciento en peso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/343,672 US8242158B1 (en) | 2012-01-04 | 2012-01-04 | Dexmedetomidine premix formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089673A1 true AR089673A1 (es) | 2014-09-10 |
Family
ID=46613447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100046A AR089673A1 (es) | 2012-01-04 | 2013-01-04 | Formulacion de premezcla de dexmedetomidina |
| ARP190103245A AR117001A2 (es) | 2012-01-04 | 2019-11-06 | Formulación de premezcla de dexmedetomidina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103245A AR117001A2 (es) | 2012-01-04 | 2019-11-06 | Formulación de premezcla de dexmedetomidina |
Country Status (36)
| Country | Link |
|---|---|
| US (10) | US8242158B1 (es) |
| EP (2) | EP2648520B1 (es) |
| JP (4) | JP5892177B2 (es) |
| KR (1) | KR101632103B1 (es) |
| CN (2) | CN103281902A (es) |
| AR (2) | AR089673A1 (es) |
| AU (1) | AU2013201069B1 (es) |
| BR (1) | BR112013008005A8 (es) |
| CA (1) | CA2806706C (es) |
| CL (1) | CL2013000815A1 (es) |
| CO (1) | CO6680698A2 (es) |
| CY (1) | CY1120521T1 (es) |
| DK (1) | DK2648520T3 (es) |
| EC (1) | ECSP13012569A (es) |
| ES (1) | ES2671749T3 (es) |
| GT (1) | GT201300055A (es) |
| HK (1) | HK1249429A1 (es) |
| HR (1) | HRP20180838T1 (es) |
| HU (1) | HUE038128T2 (es) |
| IL (1) | IL224867B (es) |
| LT (1) | LT2648520T (es) |
| MX (2) | MX375001B (es) |
| MY (2) | MY161022A (es) |
| PE (2) | PE20160681A1 (es) |
| PH (1) | PH12013500372A1 (es) |
| PL (1) | PL2648520T3 (es) |
| PT (1) | PT2648520T (es) |
| RS (1) | RS57346B1 (es) |
| SA (2) | SA113340176B1 (es) |
| SG (1) | SG191706A1 (es) |
| SI (1) | SI2648520T1 (es) |
| TR (1) | TR201809123T4 (es) |
| TW (2) | TWI574688B (es) |
| UY (1) | UY34562A (es) |
| WO (1) | WO2013103378A1 (es) |
| ZA (1) | ZA201301649B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| US8242158B1 (en) * | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
| CN106456561B (zh) | 2013-10-07 | 2020-02-28 | 帝国制药美国公司 | 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物 |
| KR20180095732A (ko) | 2013-10-07 | 2018-08-27 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물 |
| CA2924231C (en) | 2013-10-07 | 2018-04-03 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
| ES2983565T3 (es) * | 2013-10-07 | 2024-10-23 | Teikoku Pharma Usa Inc | Métodos y composiciones para tratar los síndromes de abstinencia mediante el uso de composiciones transdérmicas de dexmedetomidina no sedantes |
| MX2016007902A (es) * | 2013-12-18 | 2016-10-28 | Gnt Llc | Composiciones y metodos para el tratamiento del glaucoma. |
| FI127534B (en) * | 2014-11-10 | 2018-08-31 | Vetcare Oy | Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions |
| CN106038538A (zh) * | 2015-04-17 | 2016-10-26 | 江苏恒瑞医药股份有限公司 | 一种右美托咪定的预混合制剂 |
| CN105168122B (zh) * | 2015-09-24 | 2018-11-27 | 辰欣药业股份有限公司 | 一种盐酸右美托咪定注射液及其制备工艺 |
| US10632043B2 (en) * | 2015-11-11 | 2020-04-28 | Aurobindo Pharma Ltd | Premix formulation for parenteral use and packaging thereof |
| US20170128421A1 (en) * | 2015-11-11 | 2017-05-11 | Siva Prasad Reddy Sura | Premix formulation for parenteral use and packaging thereof |
| US9717796B1 (en) * | 2016-04-20 | 2017-08-01 | Slypharma, Llc | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
| CN107412152B (zh) * | 2016-05-24 | 2020-12-04 | 海南合瑞制药股份有限公司 | 一种盐酸右美托咪定注射液组合物 |
| EP3560495B1 (en) * | 2016-12-26 | 2021-07-28 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device |
| EP3562486B1 (en) | 2016-12-31 | 2024-03-13 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| CN107028880A (zh) * | 2017-06-09 | 2017-08-11 | 安徽赛诺制药有限公司 | 一种盐酸右美托咪定注射液的生产工艺 |
| US20190262314A1 (en) * | 2018-02-26 | 2019-08-29 | Slayback Pharma Llc | Ready-to-use dexmedetomidine compositions |
| CN108956809B (zh) * | 2018-06-04 | 2021-03-23 | 四川科伦药物研究院有限公司 | 一种检测1-(1-氯乙基)-2,3-二甲苯有关物质的方法 |
| JP7430140B2 (ja) | 2018-06-26 | 2024-02-09 | 久光製薬株式会社 | マイクロニードルデバイス及びそれを製造する方法 |
| EP3813802B1 (en) | 2018-06-27 | 2024-10-23 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| US20210267944A1 (en) | 2018-06-27 | 2021-09-02 | Bioxcel Therapeutics, Inc. | Methods for treating agitation using dexmedetomidine hydrochloride |
| CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
| CN109081811A (zh) * | 2018-09-19 | 2018-12-25 | 南京正大天晴制药有限公司 | 盐酸右美托咪定的有关物质及其制备方法 |
| JP2019048091A (ja) * | 2018-10-23 | 2019-03-28 | ニプロ株式会社 | デクスメデトミジン注射液を充填したプレフィルドシリンジ |
| US11160791B2 (en) | 2018-11-01 | 2021-11-02 | Medefil, Inc. | Dexmedetomidine injection premix formulation in ready to use (RTU) bags |
| CN111481506B (zh) * | 2019-01-25 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种包含经鼻给药的右美托咪定组合物的药物制品 |
| WO2020176807A1 (en) | 2019-02-27 | 2020-09-03 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| CN112138250B (zh) * | 2019-06-28 | 2023-04-14 | 四川普锐特药业有限公司 | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 |
| AU2020316013A1 (en) * | 2019-07-19 | 2022-02-17 | Arx, Llc | Non-sedating dexmedetomidine treatment regimens |
| CA3195133A1 (en) * | 2020-10-08 | 2022-04-14 | Frank Yocca | Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride |
| EP4085891A1 (en) | 2021-05-05 | 2022-11-09 | B. Braun Melsungen AG | Dexmedetomidine-solution in a low-density polyethylene container |
| CN113041242A (zh) * | 2021-05-18 | 2021-06-29 | 上海交通大学医学院附属仁济医院 | 右美托咪定在促进肝脏再生中的应用 |
| CN113116815A (zh) * | 2021-06-07 | 2021-07-16 | 辰欣药业股份有限公司 | 一种盐酸右美托咪定注射液的制备方法 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| JPS6058890A (ja) | 1983-09-13 | 1985-04-05 | Mizusawa Ind Chem Ltd | 感熱記録紙用填剤 |
| FI844786A0 (fi) | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
| GB2206880B (en) | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
| US5344840A (en) | 1988-02-29 | 1994-09-06 | Orion-Yhtyma Oy | 4-substituted imidazole derivatives useful in perioperative care |
| US5217718A (en) | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5124157A (en) | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| US5304569A (en) | 1989-11-13 | 1994-04-19 | Orion-Yhtyma Oy | Compositions and their use in lowering intraocular pressure |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| NZ257212A (en) | 1992-09-29 | 1996-11-26 | Inhale Therapeutic Syst | Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone |
| GB2281206A (en) | 1993-08-25 | 1995-03-01 | Orion Yhtymae Oy | Use of dexmedetomidine |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5716988A (en) * | 1994-08-08 | 1998-02-10 | Debiopharm S.A. | Pharmaceutically stable preparation of oxaliplatinum |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| DE19749724A1 (de) | 1997-11-11 | 1999-06-10 | Gruenenthal Gmbh | Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln |
| AR015744A1 (es) * | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
| US6716867B1 (en) | 1998-04-01 | 2004-04-06 | Orion Corporation | Use of dexmedetomidine for ICU sedation |
| PE20001396A1 (es) | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
| EP1121933A1 (en) | 2000-02-02 | 2001-08-08 | Pfizer Products Inc. | Premixed alatrofloxacin injectable compositions |
| US6310094B1 (en) | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| MXPA03008857A (es) | 2001-03-29 | 2004-05-24 | Baxter Int | Solucion parenteral de amiodarona premezclada y metodo para elaboracion de la misma. |
| US6806291B1 (en) * | 2003-10-09 | 2004-10-19 | The Foundation For The Lsu Health Sciences Center | Analgesic compounds, their synthesis and pharmaceutical compositions containing them |
| BRPI0604377A (pt) | 2006-10-27 | 2008-06-24 | Cristalia Prod Quimicos Farm | microemulsão óleo/água de propofol estável e pronta-para-uso |
| US20080308444A1 (en) * | 2007-06-13 | 2008-12-18 | Baxter International Inc. | Packaging system and method of alerting a practitioner |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
| US20100197694A1 (en) | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
| EP2165706A1 (en) | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
| US8100890B2 (en) * | 2008-10-15 | 2012-01-24 | Bioquiddity, Inc. | Special purpose fluid dispenser with pre-filled reservoir |
| WO2010050211A1 (ja) * | 2008-10-30 | 2010-05-06 | 国立大学法人 岡山大学 | 局所麻酔用組成物 |
| NZ596976A (en) | 2009-05-15 | 2014-05-30 | Recro Pharma Inc | Sublingual dexmedetomidine compositions and methods of use thereof |
| US8410140B2 (en) * | 2009-06-01 | 2013-04-02 | The Regents Of The University Of Michigan | Anesthetic methods and compositions |
| EP2459170A2 (en) | 2009-07-31 | 2012-06-06 | Astron Research Limited | A stable composition of ready-to-use gemcitabine injection |
| US20110152271A1 (en) | 2009-12-17 | 2011-06-23 | Gerald Horn | Compositions and methods for ophthalmic delivery of nasal decongestants |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
-
2012
- 2012-01-04 US US13/343,672 patent/US8242158B1/en active Active
- 2012-06-18 LT LTEP12823234.5T patent/LT2648520T/lt unknown
- 2012-06-18 ES ES12823234.5T patent/ES2671749T3/es active Active
- 2012-06-18 HU HUE12823234A patent/HUE038128T2/hu unknown
- 2012-06-18 PL PL12823234T patent/PL2648520T3/pl unknown
- 2012-06-18 EP EP12823234.5A patent/EP2648520B1/en not_active Revoked
- 2012-06-18 BR BR112013008005A patent/BR112013008005A8/pt not_active Application Discontinuation
- 2012-06-18 PT PT128232345T patent/PT2648520T/pt unknown
- 2012-06-18 AU AU2013201069A patent/AU2013201069B1/en active Active
- 2012-06-18 MY MYPI2013000733A patent/MY161022A/en unknown
- 2012-06-18 RS RS20180628A patent/RS57346B1/sr unknown
- 2012-06-18 SG SG2013015441A patent/SG191706A1/en unknown
- 2012-06-18 PH PH1/2013/500372A patent/PH12013500372A1/en unknown
- 2012-06-18 TR TR2018/09123T patent/TR201809123T4/tr unknown
- 2012-06-18 HR HRP20180838TT patent/HRP20180838T1/hr unknown
- 2012-06-18 MX MX2017014041A patent/MX375001B/es unknown
- 2012-06-18 CN CN2012800037344A patent/CN103281902A/zh active Pending
- 2012-06-18 EP EP18157214.0A patent/EP3345599A1/en not_active Withdrawn
- 2012-06-18 DK DK12823234.5T patent/DK2648520T3/en active
- 2012-06-18 CN CN201710644232.4A patent/CN107802624A/zh active Pending
- 2012-06-18 JP JP2013552744A patent/JP5892177B2/ja active Active
- 2012-06-18 SI SI201231312T patent/SI2648520T1/en unknown
- 2012-06-18 CA CA2806706A patent/CA2806706C/en active Active
- 2012-06-18 WO PCT/US2012/042940 patent/WO2013103378A1/en not_active Ceased
- 2012-06-18 PE PE2016000713A patent/PE20160681A1/es unknown
- 2012-06-18 KR KR1020137007434A patent/KR101632103B1/ko active Active
- 2012-06-18 MY MYPI2017000279A patent/MY188598A/en unknown
- 2012-06-18 MX MX2013003629A patent/MX2013003629A/es unknown
- 2012-06-18 PE PE2013000622A patent/PE20131166A1/es not_active Application Discontinuation
- 2012-07-03 US US13/541,524 patent/US8338470B1/en active Active
- 2012-11-15 US US13/678,260 patent/US8436033B1/en active Active
- 2012-11-15 US US13/678,148 patent/US8455527B1/en active Active
-
2013
- 2013-01-04 UY UY0001034562A patent/UY34562A/es not_active Application Discontinuation
- 2013-01-04 TW TW102100340A patent/TWI574688B/zh active
- 2013-01-04 TW TW105101909A patent/TWI593409B/zh active
- 2013-01-04 AR ARP130100046A patent/AR089673A1/es not_active Application Discontinuation
- 2013-01-05 SA SA113340176A patent/SA113340176B1/ar unknown
- 2013-01-05 SA SA115360458A patent/SA115360458B1/ar unknown
- 2013-02-21 IL IL224867A patent/IL224867B/en active IP Right Grant
- 2013-02-27 GT GT201300055A patent/GT201300055A/es unknown
- 2013-03-04 ZA ZA2013/01649A patent/ZA201301649B/en unknown
- 2013-03-06 CO CO13045125A patent/CO6680698A2/es unknown
- 2013-03-22 CL CL2013000815A patent/CL2013000815A1/es unknown
- 2013-04-19 EC ECSP13012569 patent/ECSP13012569A/es unknown
- 2013-04-22 US US13/867,861 patent/US8648106B2/en active Active
- 2013-11-12 HK HK18109069.7A patent/HK1249429A1/en unknown
- 2013-12-27 JP JP2013273409A patent/JP5990832B2/ja active Active
-
2014
- 2014-01-24 JP JP2014011233A patent/JP5927680B2/ja active Active
- 2014-02-10 US US14/177,008 patent/US9320712B2/en active Active
-
2015
- 2015-02-06 JP JP2015022203A patent/JP2015110639A/ja not_active Withdrawn
-
2016
- 2016-03-02 US US15/058,602 patent/US9616049B2/en active Active
-
2017
- 2017-02-28 US US15/444,932 patent/US10016396B2/en active Active
-
2018
- 2018-05-03 CY CY20181100462T patent/CY1120521T1/el unknown
- 2018-06-08 US US16/003,894 patent/US20180289674A1/en not_active Abandoned
- 2018-06-08 US US16/003,850 patent/US20180289673A1/en not_active Abandoned
-
2019
- 2019-11-06 AR ARP190103245A patent/AR117001A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089673A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| EA201492021A1 (ru) | Антительный состав | |
| AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
| ECSP088903A (es) | Composiciones farmacéuticas de anticuerpo antagonista anti-cd40 | |
| NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
| UA124922C2 (uk) | Модулятори ядерного транспорту та їх застосування | |
| BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| UY32602A (es) | Formulación para la administración oral de un promotor de apoptosis | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| DOP2015000170A (es) | Compuestos químicos | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| MX2014009660A (es) | Formulacion de anticuerpo anti-selectina p. | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| BR112016009214A8 (pt) | uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica | |
| BR112012016549A8 (pt) | Piperazinas como agentes antimalariais | |
| AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| AR128434A2 (es) | Composiciones y métodos de absorción transmucosa | |
| CO2019010902A1 (es) | Composición farmacéutica líquida que contiene dantrolene sódico | |
| AR104051A1 (es) | Formulación estable para administración parenteral de tapentadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |